Nature [London] 306:391-395, 1983), which causes leukemia in chickens. We used the DNA-binding domain of yeast transcriptional activator GALA to locate the transactivation region of human ets-2. The transactivation domain of ets-2 was found in the N-terminal part of the protein, which is homologous to ets-1, and can be disrupted by deletion of a stretch of acidic amino acid residues. A transactivation-deficient mutant of ets-2 failed to transform Rat-i cells and suppressed the transforming activity of coexpressed wild-type ets-2. A mutation in the putative DNA-binding region of ets-2 abolished transforming activity. We show that the motif crucial for ets-2 transactivation capability is necessary for transforming activity in Rat-i cells. Mutant ets-2 protein that lacks the transactivation domain has a dominant negative effect on transformation by wild-type ets-2. We were unable to detect ets-2-dependent transcriptional regulation of several enhancers containing ets-binding motifs.
The human ets-2 proto-oncogene is one of the homologs of the v-ets gene, found in avian acutely transforming retrovirus E26 (D. Leprince [391] [392] [393] [394] [395] 1983 ), which causes leukemia in chickens. We used the DNA-binding domain of yeast transcriptional activator GALA to locate the transactivation region of human ets-2. The transactivation domain of ets-2 was found in the N-terminal part of the protein, which is homologous to ets-1, and can be disrupted by deletion of a stretch of acidic amino acid residues. A transactivation-deficient mutant of ets-2 failed to transform Rat-i cells and suppressed the transforming activity of coexpressed wild-type ets-2. A mutation in the putative DNA-binding region of ets-2 abolished transforming activity. We show that the motif crucial for ets-2 transactivation capability is necessary for transforming activity in Rat-i cells. Mutant ets-2 protein that lacks the transactivation domain has a dominant negative effect on transformation by wild-type ets-2. We were unable to detect ets-2-dependent transcriptional regulation of several enhancers containing ets-binding motifs.
ets-2 TA domain is located in the N-terminal region of the protein. ets-2 protein has been shown to be expressed in a variety of rapidly growing cell types (1) , including most cell lines grown in vitro. We hypothesized that ets-2, being a transcriptional factor (5, 22) , requires an intact transactivation (TA) domain to produce its biologic effect. Deletion of this functional domain of ets-2 might result in a protein that can be used to suppress normal function of ets-2 by competing for DNA binding with the same sites. One of the aims of this study was to localize the TA region of ets-2. In our preliminary experiments, by using reporter assays, we cotransfected chloramphenicol acetyltransferase (CAT) plasmids driven by promoters containing ets motifs together with ets-2 expression vectors. These data, as well as band shift studies, failed to demonstrate either high-affinity interaction of ets-2 protein with either PEA3-like motifs (PU.1 binding site from simian virus 40, ets-1 binding site from murine sarcoma virus long terminal repeat, and PEA3 site from the pyrimidine enhancer) or transcriptional activation of artificial promoters containing multiple PEA3-like sites (data not shown). Recent results with ets-2 (5) and other ets-related proteins, including GABP-alpha (10, 26) and Elk-1 (8), suggest that protein-protein interactions can be important in site specificity and affinity of binding of DNA. In this study, we used a well-established GAL4 system to localize a potential TA domain of ets-2. The N-terminal 147 amino acid residues of yeast transcriptional activator GAL4 contain a highly specific DNA-binding domain as well as a nuclear localization signal (15, 25) . We cloned parts of ets-2 cDNA coding for different regions of ets-2 proteins into a GALM expression vector (21) , producing a number of fusion constructs (Fig. 1 ). GAL4-ets-2 gene fusions were constructed by cloning fragments of human ets-2 cDNA, a generous gift from Anne Gegonne (2), into a GALM expression vector, a derivative of GAL4(1-147), described previously (14, 21) . pGALVP16, a GAL4 chimera which is a * Corresponding author. strong transcriptional activator (20) , was used as a positive control for transcriptional activation.
pGAL1-293 contains a 921-bp SacII-SacI fragment and pGAL1-476 contains a complete coding sequence of ets-2 (SacII-BstXI fragment). An EheI-BstXI fragment coding for 269 C-terminal amino acids of ets-2 was used to produce pGAL207-476, and 400-bp SacII-Pst and 567-bp PstI-PstI ets-2 fragments were used to make pGAL1-135 and pGAL135-324 plasmids. The pGAL357-476 effector plasmid contains a PstI-SacII fragment of about 900 bp and encodes a C-terminal ets-2 fragment; pGAL1-109 contains an EheI fragment, coding for 109 N-terminal amino acids; and pGAL109-207 was made with an EheI fragment coding for amino acids (aa) 109 to 207 of human ets-2.
To construct a GAL4 fusion with a deletion mutant of ets-2 (A140-185, pGALATA), ets-2 TA-mutant cDNA was cut from plasmid pCMTA (Fig. 2) (20) . GALA chimera expression vectors described as activators were cotransfected with G5E1BCAT, a reporter plasmid having five GALA DNA-binding sites, into CHO cells. A CMV CAT plasmid served as a strong positive control for CAT activity. Another positive control was a GAL4-VP16 expression vector, containing part of the strong acidic-type transcriptional activator of VP16 from herpes simplex virus. The activation strength of each construct in this assay was calculated relative to the activity of empty vector pGALM, expressing only the 147-aa DNA-binding domain of GALM, and normalized for protein content in samples taken for CAT assay. At the bottom, the domain that is necessary for TA by human ets-2 protein is shown; dots indicate a stretch of regularly spaced acidic amino acid residues. measured and used to correct for variation in efficacy of transfection (4) .
Immunoprecipitation with polyclonal rabbit antiserum against GAL4 protein revealed similar levels of expression of these constructs in transfected COS-1 cells (Fig. 3) (6, 13) . To perform this analysis, cells were starved for methionine for 1 h at 48 h after transfection and then labelled in vivo for 3 h with 200 ,uCi of 35S-Translabel reagent (ICN Biomedicals Inc.) per ml in methionine-free Dulbecco modified Eagle medium. Nuclear extracts were prepared from these cells as described previously (11); lysed nuclei were diluted to 1 ml with PBSTDS (10 mM dibasic sodium phosphate [pH 7.2], 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 0.2% sodium azide, 0.004% sodium fluoride) at 4°C. To try to locate precisely the domain involved in TA, we produced a number of additional fusion constructs (Fig. 1) . None, except an ets-2 fragment from aa 135 to 324, had activity. We noted that construct GAL1-293 (which had the highest TA activity) as well as GAL135-324 contains a stretch of negatively charged amino acid residues, characteristic of the acid-type family of transcriptional regulators (14, 19) . Deletion of 45 codons (aa 141 to 184) from ets-2 cDNA resulted in a GAL4-ets-2 fusion construct (GALATA) that had no TA activity (Fig. 1) . This is the most conserved region of ets-1 and ets-2 proteins outside their major C-terminal region of homology (27) . Nevertheless, this region is not sufficient for TA, since the minimal domain that activated CAT production included aa 135 to 324 of ets-2 protein (Fig. 1) . We have noted that decreasing the size of this fragment also removes one or both cysteine residues found at positions 145 and 228 of ets-2 protein (Fig. 1) The lower of the two bands seen in lanes 1, 2, 3, and 5 is likely to be a proteolysis product of GALA fusions, since it is not detected in unfractionated, whole-cell extracts (not shown).
To study the consequences of ets-2 expression in vivo and to determine whether transcriptional activation is required for transformation by ets-2, we used Rat-1 cells as an assay system for transformation.
Human ets-2 expression constructs, coding for wild-type ets-2 and two of its mutant derivatives, TA-ETS and TS-ETS, were produced by polymerase chain reaction (PCR) with ets-2 cDNA. To construct a deletion mutant of ets-2 lacking the coding sequence for 45 aa (140 to 185), two PCRs, A and B, with oligonucleotides I (5'-GTAGTGCA GAAAGCl-lCCCGCAGCGGCAGGATGAAT-3') and II (5'-GTCGGAGAAITCATGCCGAACCTCTGCAG-3') (amplification of N-terminal region) and with oligonucleotides III (5'-GTCGGAGAA1JCACACCTCACCTCCGTT-3') and IV (5'-GTCGCAGiGATCCGGTCAGGATGGGC(lCCCAC T-3') (amplification of C-terminal region), respectively, and full-length ets-2 cDNA, produced fragments coding for aa 1 to 140 and 185 to 476. Following treatment of reaction A and B products with restriction enzymes, PCR products encoding both N-terminal and C-terminal mutated parts of ets-2 were then cloned into pCDNAI expression vector, a derivative of pCM8 (23 Fig. 4 represent the averages. Plasmids expressing an activated Ha-ras oncogene and an empty pcDNAI vector were used as positive and negative controls, respectively, for transformation.
The wild-type ets-2 expression construct efficiently transformed Rat-1 cells to grow in soft agar, whereas both mutant constructs had negligible transforming activity (Fig. 4) . This is in agreement with previous data showing that overexpres- sion of murine ets-2 in NIH 3T3 cells results in transformation and tumorigenicity of transformed cells in nude mice (24) . In-frame deletion of the TA domain from ets-2 completely abolished its transforming potential (Fig. 4) (Fig. 4) 
